FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions

Nature Reviews Clinical Oncology, Published online: 29 February 2024; doi:10.1038/s41571-024-00869-zFGFR inhibitors are now approved for use in patients with advanced-stage urothelial carcinoma, cholangiocarcinoma and myeloid or lymphoid neoplasms that harbour certain FGFR alterations. Nonetheless, challenges such as tolerability and acquired resistance limit the clinical potential of these agents. In this Review, the authors summarize the available clinical data on FGFR inhibitors, describe promising novel agents and highlight future research directions that might optimize the efficacy of FGFR-targeted therapies.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research